Opus Genetics CFO sells 28,000 shares at $4.5433

Opus Genetics’ CFO reported a 28,000-share sale, partly for tax withholding and partly under a pre-arranged Rule 10b5-1 plan.

Rhea-AI Filing Summary

Opus Genetics, Inc. (IRD) reported that its Chief Financial Officer, Robert E. Gagnon, sold 28,000 shares of common stock on September 3, 2026. The weighted average sale price was $4.5433 per share, in multiple trades between $4.29 and $4.79, leaving him with 556,375 shares held directly. A portion of the shares was sold automatically to cover tax withholding from vesting restricted stock units, and the remainder was sold under a pre-arranged Rule 10b5-1 trading plan adopted on April 30, 2026.

Insider Trade Summary

Net Seller: 28,000 shares

Net Sell 1 txn

Insider Gagnon Robert E.

Role Chief Financial Officer

Sold 28,000 shs ($127K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	28,000	$4.5433	$127K

Holdings After Transaction: Common Stock — 556,375 shares (Direct)

Footnotes (2)

1. F1. A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer.
2. F2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 28,000 shares Weighted average sale price: $4.5433 per share Sale price range: $4.29–$4.79 per share +2 more

5 metrics

Shares sold 28,000 shares Common stock sale reported for September 3, 2026

Weighted average sale price $4.5433 per share Average price across multiple sale transactions on September 3, 2026

Sale price range $4.29–$4.79 per share Range of prices for multiple transactions included in the reported sale

Shares owned after transaction 556,375 shares Direct holdings of the CFO after the September 3, 2026 sale

Rule 10b5-1 plan adoption date April 30, 2026 Date the CFO adopted the pre-arranged trading plan covering part of the sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, restricted stock units, tax withholding obligations

4 terms

Rule 10b5-1 trading plan regulatory

"The remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in column 4 represents the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

restricted stock units financial

"tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations"

FAQ

What insider transaction did Opus Genetics (IRD) report for its CFO?

Opus Genetics reported that its CFO, Robert E. Gagnon, sold 28,000 shares of common stock on September 3, 2026. After the sale, he directly held 556,375 shares of Opus Genetics common stock.

At what prices were the Opus Genetics (IRD) shares sold in this Form 4?

The reported weighted average price was $4.5433 per share. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive, according to the filing’s footnote.

Why were some of the Opus Genetics (IRD) shares sold by the CFO automatically?

A portion of the reported shares was sold automatically as required by Opus Genetics to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units held by the CFO.

Was the Opus Genetics (IRD) CFO’s share sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the remainder of the shares, beyond those sold for tax withholding, was sold pursuant to a Rule 10b5-1 trading plan adopted by the CFO on April 30, 2026.

How many Opus Genetics (IRD) shares does the CFO hold after this transaction?

Following the September 3, 2026 sale, the CFO is reported to directly own 556,375 shares of Opus Genetics common stock, as shown in the post-transaction holdings column.

Does the Form 4 for Opus Genetics (IRD) indicate how detailed pricing data can be obtained?

Yes. A footnote states that the CFO will provide Opus Genetics, any securityholder, or SEC staff, upon request, with full information on the number of shares sold at each separate price within the $4.29–$4.79 range.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:06 PM Accepted by SEC EDGAR 09/08/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gagnon Robert E.

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S(1)		28,000	D	$4.5433(2)	556,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. A portion of the shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer, to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026. The Rule 10b5-1 trading plan is a pre-arranged written trading plan pursuant to which shares of the Issuer's common stock are sold automatically based on a predetermined formula that was established by the Reporting Person at a time when the Reporting Person was not aware of any material nonpublic information about the Issuer.

2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $4.29 to $4.79, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Amy Rabourn, by Power of Attorney	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)